RE: GMP product7 Dec 2016 12:38
I think you'll find that Novartis hasn't closed down the CAR-T cell research but re-organised its divisions internally so it disappeared as a separate entity. They seem to have at least one more product in development with OXB, although we don't know exactly what it is, and beyond that perhaps others. Given the staggering success so far of immunological modification, I doubt that they are likely to abandon this space when they are, arguably perhaps, in the lead to market.